Novacyt S.A. (AIM:NCYT)

Market Cap	36.78M +32.8%
Revenue (ttm)	20.03M +2.0%
Net Income	-22.88M
EPS	-0.32
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	166,025
Open	50.00
Previous Close	50.40
Day's Range	48.80 - 51.20
52-Week Range	26.60 - 86.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 30, 2026

About Novacyt

Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2006
• Employees: 234
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: NCYT

Financial Performance

In 2025, Novacyt's revenue was 20.03 million, an increase of 2.03% compared to the previous year's 19.63 million. Losses were -22.88 million, -45.20% less than in 2024.